Answers are grounded in this paper and cite their sources.
In patients with SLE from North East Asia, belimumab significantly improved disease activity, while reducing prednisone use, with no new safety issues.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: